Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tempest Therapeutics ( (TPST) ) just unveiled an announcement.
On February 11, 2026, Tempest Therapeutics announced it would post an updated corporate presentation outlining a diversified, partner-funded oncology pipeline spanning discovery through Phase 2, anchored by its CD19/BCMA and CD70/CD70 CAR-T programs and other targeted candidates. The presentation highlights TPST-2003, a dual-target CD19/BCMA CAR-T for relapsed or refractory multiple myeloma with extramedullary disease, which has shown high response rates and a favorable safety profile in early trials in China, and details a series of value-driving, largely partner-funded milestones through 2027 that could materially influence the company’s development trajectory and capital needs.
The company details how strategic partnerships, including with Novatim Immune Therapeutics and the U.S. National Cancer Institute, are funding key clinical activities such as Phase 2b and registrational studies, thereby reducing Tempest’s direct cash burden and enabling more disciplined capital deployment. For stakeholders, the roadmap of Phase 1–2b readouts, planned IND and BLA filings, and expansion of dual CAR-T programs into autoimmune indications underscores both the potential for future inflection points in the company’s valuation and the execution and regulatory risks inherent in advancing first-in-class and best-in-class cell therapies across multiple geographies.
The most recent analyst rating on (TPST) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and significant cash burn with a shrinking equity cushion). Technicals remain soft with price below key longer-term averages and negative MACD. Corporate events are mixed (Nasdaq compliance risk vs. governance approvals), and valuation metrics offer limited support due to negative earnings and no dividend.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is an oncology-focused biopharmaceutical company developing advanced cancer therapies, including small molecules and cell therapies, with a strong emphasis on CAR-T treatments for hematologic malignancies and solid tumors. Its pipeline targets indications such as relapsed or refractory multiple myeloma, renal cell carcinoma, hepatocellular carcinoma and autoimmune diseases, often in partnership with academic and industry collaborators to share development costs and expand global reach.
Average Trading Volume: 153,939
Technical Sentiment Signal: Sell
Current Market Cap: $11.83M
See more insights into TPST stock on TipRanks’ Stock Analysis page.